Get the Stockscreener App
3.99
1.24%
-0.05
Titan Pharmaceuticals Inc De stock is traded at $3.99, with a volume of 2,018.
It is down -1.24% in the last 24 hours and down -6.34% over the past month.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$4.04
Open:
$4
24h Volume:
2,018
Relative Volume:
0.04
Market Cap:
$3.65M
Revenue:
$61,000
Net Income/Loss:
$-5.46M
P/E Ratio:
-0.6101
EPS:
-6.54
Net Cash Flow:
$-6.76M
1W Performance:
-1.97%
1M Performance:
-6.34%
6M Performance:
+22.77%
1Y Performance:
-31.68%
1-Day Range:
$3.91
$4.00
1-Week Range:
$3.70
$4.38
52-Week Range:
$3.03
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Name
Titan Pharmaceuticals Inc De
Sector
Industry
Phone
(650) 244-4990
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Compare TTNP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
3.99 | 5.39M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-19 | Initiated | Maxim Group | Buy |
| Nov-10-17 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Stock (TTNP) Latest News
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
Acurx Pharmaceuticals Plans Major 1:20 Reverse SplitKey Details for Nasdaq Compliance - Stock Titan
Lexicon Pharmaceuticals Meets $1 Minimum Share Price, Secures Critical Nasdaq Listing Status - Stock Titan
Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 - Stock Titan
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders - GlobeNewswire Inc.
Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership - Stock Titan
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire
What analysts say about Titan Pharmaceuticals Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Rani Therapeutics Secures $3M Financing Deal: Biotech Firm Prices Shares at $0.40 in Strategic Offering - Stock Titan
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
ESSA Pharma Shareholders to Receive $1.91 Cash Plus CVR in XenoTherapeutics Acquisition Deal - Stock Titan
RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan
MIST gets FDA review nod; PDUFA set for Dec 13 2025 – covenant aligned | MIST SEC FilingForm 8-K - Stock Titan
FDA Sets New December 2025 Decision Date for Milestone's PSVT Nasal Spray, Secures $75M Funding - Stock Titan
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development - Stock Titan
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Verrica Hits Record Quarter: YCANTH Sales Surge 32.8% as $8M Partnership Milestone Achieved - Stock Titan
Citius Pharma Dodges Delisting: Stock Maintains $1+ Price for 10 Straight Days, Secures Nasdaq Future - Stock Titan
Merck & Co.: A Pharma Titan At A Discount (NYSE:MRK) - Seeking Alpha
Rigel Pharmaceuticals Grants 23,075 Stock Options to 10 New Hires with 4-Year Vesting Terms - Stock Titan
COLL announces $150M share buyback through 2026 – cash-funded | COLL SEC FilingForm 8-K - Stock Titan
XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan
Cyclacel Announces Major Share Restructuring: 23.7M Shares Consolidating to 1.58M - Stock Titan
Verrica Secures $18M in Milestones as Phase 3 Wart Treatment Trial Targets Massive Untapped Market - Stock Titan
Elite Pharmaceuticals Crushes Earnings: 81% Profit Jump Reveals Massive Growth from New Drug Launch - Stock Titan
Titan Pharmaceuticals Raises $600,000 Through Convertible Preferred Stock at $3.40 Conversion Price - Stock Titan
Reviva Pharma Raises $10M: New Offering Includes Warrants with 5-Year Exercise Window at $0.50 - Stock Titan
Adial Secures Critical US Manufacturing Deal With Thermo Fisher for Alcohol Use Disorder Drug - Stock Titan
InMed's Alzheimer's Drug Shows Promise in Breakthrough Preclinical Study | INM SEC FilingForm 8-K - Stock Titan
Elite Pharmaceuticals to Reveal Full Year 2025 Performance: Key Earnings Call Details Inside - Stock Titan
Inozyme Pharma Halts Annual Meeting as BioMarin Acquisition Nears Completion - Stock Titan
AGIO files Form S-8 to add shares to 2023 Stock Incentive Plan - Stock Titan
Lobe Sciences Secures $26M for Novel Chronic Cluster Headache Drug Development | LOBEF Stock News - Stock Titan
Endo Offloads International Pharma Unit for $105M: Deal Structure Reveals Upfront Cash Plus Milestone Payments - Stock Titan
NRx Pharmaceuticals Taps Top Biotech IR Firm ahead of Critical FDA Filings and Clinic Acquisitions - Stock Titan
Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan
Biotech to Environmental Services: Windtree's $12M Revenue Play in $85B Waste Management Market - Stock Titan
Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World
Apellis Reveals New Insights at Goldman Sachs Healthcare Conference: How to Watch Live - Stock Titan
Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
ORIC Lands Massive $125M Investment Led by SR One, Extending Runway Through Critical Phase 3 Cancer Trial - Stock Titan
Clinical Data: Vanda Unveils Key Bioequivalence Study Results for Next-Gen Psychiatric Drug at Major Conference - Stock Titan
Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan
Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan
Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):